📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 20:56
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
4% YoY Revenue Growth in Q1 FY27; Consolidated PAT Declines 13% to Rs 1.97 Cr
Kilitch Drugs reported a modest 4% YoY increase in consolidated revenue to Rs 44.88 Cr for Q1 FY27. However, consolidated net profit declined by 13% YoY to Rs 1.97 Cr, primarily dragged down by losses in its foreign subsidiary, Kilitch Estro Biotech PLC, which reported a loss of Rs 2.87 Cr. Standalone operations remained robust with a PAT of Rs 5.05 Cr, suggesting the core Indian business is subsidizing international expansion losses. Total comprehensive income was supported by a significant Rs 5.00 Cr gain in other comprehensive income, likely due to currency fluctuations or asset revaluation.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing steady standalone performance but increased drag from international subsidiaries.
Why it mattersThe results highlight the execution risk of the company's international expansion strategy; while standalone Indian operations are profitable, the consolidated bottom line is sensitive to the performance of foreign units and exchange rate volatility.
Consolidated Revenue (Q1): Rs 44.88 CrConsolidated PAT (Q1): Rs 1.97 CrRevenue vs TTM Revenue: 19.1%Foreign Subsidiary Loss: Rs 2.87 CrStandalone PAT: Rs 5.05 Cr
📅 Short termThe stock may face mild pressure due to the YoY decline in consolidated PAT and the significant sequential drop in revenue compared to Q4 FY26.
📈 Long termThe long-term outlook depends on the company's ability to scale its high-margin parenteral range and turn its international subsidiaries profitable.
⚠ Risk flags
- Loss-making foreign subsidiaries
- High sequential revenue volatility
- Significant impact of Other Comprehensive Income on total earnings
Key Highlights
Consolidated Revenue increased 4% YoY to Rs 44.88 Cr from Rs 43.14 Cr in the previous year's quarter.
Consolidated PAT fell 13% YoY to Rs 1.97 Cr, down from Rs 2.26 Cr in Q1 FY26.
Foreign subsidiary Kilitch Estro Biotech PLC reported a loss of Rs 2.87 Cr on revenue of Rs 3.97 Cr.
Standalone PAT stood at Rs 5.05 Cr, representing a 5.4% YoY growth over standalone Q1 FY26 PAT of Rs 4.79 Cr.
Total Comprehensive Income reached Rs 6.97 Cr, aided by Rs 5.00 Cr in other comprehensive income.
👀 What to Watch
Monitor the path to profitability for the foreign subsidiary Kilitch Estro Biotech PLC, as its current losses are significantly eroding standalone profits. Watch for stabilization in quarterly revenue, which saw a sharp 50% sequential decline from the outlier Q4 FY26 performance.
Kilitch Drugs Commences Nutraceutical Manufacturing at New Raigad Plant
Kilitch Drugs (India) Limited has officially commenced operations at its new Nutraceutical Manufacturing Block located in Raigad, Maharashtra. The facility, situated at Village Maldev, Taluka Pen, began commercial production on June 17, 2026. This expansion marks a strategic move into the nutraceutical segment, which is expected to diversify the company's revenue streams beyond traditional pharmaceuticals. The commencement follows the company's regulatory compliance under SEBI Listing Obligations.
Key Highlights
Commencement of operations at the new Nutraceutical Manufacturing Block on June 17, 2026.
Facility located at 24/2/1/1, Village: Maldev, Taluka: Pen, District: Raigad, Maharashtra.
Strategic expansion into the high-growth nutraceutical sector to enhance product portfolio.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should monitor the incremental revenue contribution from this new nutraceutical block in the upcoming quarterly results. The expansion suggests a positive outlook for capacity growth and market diversification.
Kilitch Drugs Reports 23% PAT Growth in Q4 FY26; FY26 Revenue at ₹188.6 Crore
Kilitch Drugs (India) Limited reported a strong Q4 FY26 with net sales growing 27.8% year-on-year to ₹71.97 crore. Net profit for the quarter rose 23.1% to ₹14.00 crore compared to ₹11.37 crore in the previous year's corresponding quarter. On a full-year basis, the company maintained steady performance with total income reaching ₹202.42 crore and PAT at ₹32.40 crore. Notably, the company completed a 1:1 bonus issue in March 2026, which has adjusted the earnings per share figures for the period.
Key Highlights
Q4 FY26 Net Sales increased by 27.8% YoY to ₹7,196.88 Lakhs.
Quarterly Net Profit (PAT) grew 23.1% YoY to ₹1,399.90 Lakhs.
Full-year FY26 Total Income stood at ₹20,242.28 Lakhs, a 3.6% increase over FY25.
Successfully executed a 1:1 bonus issue with allotment of 1,74,80,782 shares on March 25, 2026.
Export Product Registration and Commission expenses stood at ₹24.39 crore for the full year.
👀 What to Watch
Investors should monitor the company's export-driven growth momentum which significantly boosted Q4 results. The 1:1 bonus issue has improved liquidity, but investors should evaluate the stock based on its steady 4% annual PAT growth.
Kilitch Drugs Allots 1.75 Crore Bonus Shares in 1:1 Ratio
Kilitch Drugs (India) Limited has officially approved the allotment of 1,74,80,782 bonus equity shares to its shareholders. The allotment is based on a 1:1 ratio, meaning shareholders receive one new share for every one share held as of the record date, March 24, 2026. This corporate action has resulted in the doubling of the company's paid-up equity share capital from Rs. 17.48 crore to Rs. 34.96 crore. The new shares will rank pari-passu with existing shares, effectively increasing the stock's liquidity in the market.
Key Highlights
Allotment of 1,74,80,782 bonus equity shares with a face value of Rs. 10 each.
Bonus issue ratio maintained at 1:1 for all eligible shareholders as of March 24, 2026.
Total paid-up share capital increased from Rs. 17,48,07,820 to Rs. 34,96,15,640.
Total number of equity shares post-allotment stands at 3,49,61,564.
The board meeting concluded on March 25, 2026, finalizing the issuance process.
👀 What to Watch
Investors should account for the increased share count in their portfolios and the proportional adjustment in the market price. The bonus issue is a positive signal of management's confidence and aims to improve retail participation through better liquidity.
Kilitch Drugs Sets March 24, 2026 as Record Date for 1:1 Bonus Issue
Kilitch Drugs (India) Limited has officially announced March 24, 2026, as the record date for its 1:1 bonus share issue. Shareholders holding the company's equity shares of face value Rs. 10 each as of the record date will be eligible to receive one additional share for every share held. The deemed date for the allotment of these bonus shares is set for March 25, 2026. This move follows the necessary shareholder approvals and aims to increase the liquidity of the stock in the market.
Key Highlights
Bonus issue ratio of 1:1 (one new share for every one existing share held)
Record date for determining eligibility is Tuesday, March 24, 2026
Deemed date of allotment for bonus shares is Wednesday, March 25, 2026
Face value of the equity shares remains at Rs. 10 per share
👀 What to Watch
Existing shareholders should hold their positions through the record date to receive the bonus shares. New investors should be aware that the stock price will adjust downwards proportionally on the ex-bonus date.
Kilitch Drugs Approves 1:1 Bonus Issue and Increase in Authorized Capital at EGM
Kilitch Drugs (India) Limited successfully conducted its Extraordinary General Meeting (EGM) on March 13, 2026. Shareholders approved the issuance of bonus shares in a 1:1 ratio, meaning investors will receive one additional share for every share held. The meeting also authorized an increase in the company's share capital and necessary amendments to the Memorandum of Association. The record date for the bonus allotment will be determined and announced by the Board in due course.
Key Highlights
Approval of 1:1 Bonus Issue for all eligible shareholders as of the upcoming record date
Resolution passed to increase the Authorized Capital of the company and amend the Memorandum of Association
EGM held on March 13, 2026, with participation from 3 promoter group members and 45 public shareholders
The meeting was conducted via video conferencing and concluded within 12 minutes with all resolutions transacted
👀 What to Watch
Existing shareholders should monitor for the announcement of the record date to ensure eligibility for the 1:1 bonus shares. Note that while share count will double, the stock price will adjust proportionally on the ex-bonus date.
Kilitch Drugs Approves 1:1 Bonus Issue and Capital Increase at EGM
Kilitch Drugs (India) Limited successfully conducted an Extraordinary General Meeting on March 13, 2026. The shareholders approved a 1:1 bonus share issue, which will double the total number of equity shares. Additionally, the company received approval to increase its authorized share capital to support the bonus issuance. The Board of Directors will determine the record date for the allotment in due course.
Key Highlights
Approved 1:1 bonus share issuance to existing shareholders as of the upcoming record date.
Authorized the increase of the company's share capital and subsequent amendment of the Memorandum of Association.
The EGM was held via video conferencing with participation from 48 members (3 promoters and 45 public).
The meeting was brief, commencing at 11:30 am and concluding at 11:42 am on March 13, 2026.
👀 What to Watch
Investors should track the upcoming announcement regarding the record date to qualify for the 1:1 bonus. Note that the stock price will adjust proportionally on the ex-bonus date to reflect the increased share count.
Kilitch Drugs Announces 1:1 Bonus Issue and Increase in Authorized Capital
Kilitch Drugs (India) Limited has scheduled an Extraordinary General Meeting (EGM) on March 13, 2026, to seek shareholder approval for a 1:1 bonus share issuance. The company plans to capitalize up to INR 17.48 crore from its Free Reserves or Securities Premium to issue approximately 1.75 crore new equity shares. To facilitate this, the authorized share capital will be increased from INR 25 crore to INR 40 crore. Shareholders on record as of March 4, 2026, will be eligible for e-voting on these proposals.
Key Highlights
Proposed 1:1 bonus issue, providing one new equity share for every one existing share held
Increase in Authorized Share Capital from INR 25,00,00,000 to INR 40,00,00,000
Capitalization of a sum not exceeding INR 17,48,07,820 from reserves for the bonus issue
EGM to be held on March 13, 2026, with remote e-voting from March 9 to March 12, 2026
Cut-off date for determining e-voting eligibility is March 4, 2026
👀 What to Watch
Investors should monitor the official announcement of the Record Date following the EGM approval to ensure eligibility for the bonus shares. While the number of shares will double, the stock price will adjust proportionally, improving liquidity for retail participants.
Kilitch Drugs Announces 1:1 Bonus Issue and Q3 FY26 Results; Revenue Jumps 170% YoY
Kilitch Drugs (India) Limited has recommended a 1:1 bonus issue, providing one free equity share for every share held, subject to shareholder approval. For Q3 FY26, the company reported a massive 170% year-on-year surge in standalone revenue to ₹44.67 crore, although net profit declined to ₹4.89 crore from ₹6.88 crore in the same period last year. The company is also increasing its authorized share capital to ₹40 crore to facilitate the bonus issuance. These developments follow a recent ₹49.92 crore rights issue aimed at funding a Greenfield Project at Pen, signaling aggressive expansion.
Key Highlights
Approved 1:1 Bonus Issue by capitalizing free reserves and securities premium of ₹17.48 crore.
Standalone Q3 FY26 revenue from operations rose to ₹44.67 crore versus ₹16.51 crore in Q3 FY25.
Net profit for the quarter stood at ₹4.89 crore, impacted by higher material costs and export commissions.
Authorized share capital increased from ₹25 crore to ₹40 crore to accommodate the new equity base.
Recently completed a ₹49.92 crore rights issue in August 2025 for capital expenditure on a Greenfield Project.
👀 What to Watch
The 1:1 bonus issue is a positive signal for retail liquidity, though investors should monitor the compression in net profit margins despite the high revenue growth. The progress of the Greenfield Project at Pen will be the primary driver for long-term value creation.
Kilitch Drugs Announces 1:1 Bonus Issue and Reports Q3 FY26 Results
Kilitch Drugs (India) Limited has approved a 1:1 bonus issue, meaning shareholders will receive one additional share for every one share held. The company reported standalone net sales of ₹44.67 crore for Q3 FY26, a significant jump from ₹16.51 crore in the same quarter last year. However, net profit for the quarter declined to ₹4.89 crore from ₹6.88 crore YoY, primarily due to a high base of 'Other Income' in the previous year. The board also approved increasing the authorized share capital from ₹25 crore to ₹40 crore to facilitate this corporate action.
Key Highlights
Approved 1:1 bonus issue of equity shares of face value ₹10 each
Standalone Net Sales grew to ₹44.67 crore in Q3 FY26 from ₹16.51 crore in Q3 FY25
Net Profit after tax stood at ₹4.89 crore for the quarter ended December 31, 2025
Authorized share capital increased to ₹40 crore from ₹25 crore subject to member approval
Estimated completion date for bonus share credit is April 10, 2026
👀 What to Watch
The 1:1 bonus issue will increase liquidity and make the stock more affordable for retail investors, though it does not change the company's fundamental value. Investors should monitor the strong growth in core operational revenue while keeping an eye on the volatility of non-operating income.
Kilitch Drugs Announces 1:1 Bonus Issue; Q3 Revenue Surges to ₹44.67 Crore
Kilitch Drugs (India) Limited has approved a 1:1 bonus issue, meaning shareholders will receive one additional share for every share held as of the record date. The company reported a significant jump in standalone revenue for Q3 FY26 to ₹4,467 lakhs, up from ₹1,651 lakhs in the same quarter last year. However, standalone net profit for the quarter declined to ₹489 lakhs from ₹688 lakhs YoY due to increased operational expenses. The board has also proposed increasing the authorized share capital from ₹25 crore to ₹40 crore to facilitate the bonus issuance.
Key Highlights
Approved 1:1 bonus issue by capitalizing ₹17.48 crore from free reserves and securities premium.
Standalone Q3 FY26 revenue grew 170% YoY to ₹4,467 lakhs from ₹1,651 lakhs.
Standalone Net Profit for Q3 FY26 stood at ₹489.08 lakhs compared to ₹688.30 lakhs YoY.
Authorized share capital increased to ₹40 crore from ₹25 crore, subject to shareholder approval.
Bonus shares are expected to be credited or dispatched by April 10, 2026.
👀 What to Watch
Investors should maintain a positive outlook due to the bonus issue which will enhance liquidity, though the dip in net profit despite high revenue growth warrants a closer look at margin pressures. Monitor the EGM on March 13, 2026, for final approval and the subsequent announcement of the record date.
